Estimated cost savings of increased use of intravenous tissue plasminogen activator for acute ischemic stroke in Canada

Todd R. Yip, Bart M Demaerschalk

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

BACKGROUND AND PURPOSE - Intravenous tissue plasminogen activator (tPA) is an economically worthwhile but underused treatment option for acute ischemic stroke. We sought to identify the extent of tPA use in Canadian medical centers and the potential savings associated with increased use nationally and by province. METHODS - We determined the nationwide annual incidence of ischemic stroke from the Canadian Institute of Health Information. The proportion of all ischemic stroke patients who received tPA was derived from published data. Economic analyses that report the expected annual cost savings of tPA were consulted. The analysis was conducted from the perspective of a universal health care system during 1 year. We estimated cost-savings with incrementally (eg, 2%, 4%, 6%, 8%, 10%, 15%, and 20%) increased use of tPA for acute ischemic stroke nationally and provincially. RESULTS - The current average national tPA utilization is 1.4%. For every increase of 2 percentage points in utilization, $757 204 (Canadian) could possibly be saved annually (95% CI maximum loss of $3 823 992 to a maximum savings of $2 201 252). With a 20% rate, >$7.5 million (Canadian) could be saved nationwide the first year. CONCLUSIONS - We estimate that even small increases in the proportion of all Canadian ischemic stroke patients receiving tPA could result in substantial realized savings for Canada's health care system.

Original languageEnglish (US)
Pages (from-to)1952-1955
Number of pages4
JournalStroke
Volume38
Issue number6
DOIs
StatePublished - Jun 2007

Fingerprint

Cost Savings
Tissue Plasminogen Activator
Canada
Stroke
Delivery of Health Care
Annual Reports
Economics
Incidence
Health

Keywords

  • Acute ischemic
  • Costs
  • Economics
  • Medical
  • Stroke
  • Thrombolysis
  • Tissue plasminogen activator

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Neuroscience(all)

Cite this

Estimated cost savings of increased use of intravenous tissue plasminogen activator for acute ischemic stroke in Canada. / Yip, Todd R.; Demaerschalk, Bart M.

In: Stroke, Vol. 38, No. 6, 06.2007, p. 1952-1955.

Research output: Contribution to journalArticle

@article{5edd03e39985420eaa985169fa962df1,
title = "Estimated cost savings of increased use of intravenous tissue plasminogen activator for acute ischemic stroke in Canada",
abstract = "BACKGROUND AND PURPOSE - Intravenous tissue plasminogen activator (tPA) is an economically worthwhile but underused treatment option for acute ischemic stroke. We sought to identify the extent of tPA use in Canadian medical centers and the potential savings associated with increased use nationally and by province. METHODS - We determined the nationwide annual incidence of ischemic stroke from the Canadian Institute of Health Information. The proportion of all ischemic stroke patients who received tPA was derived from published data. Economic analyses that report the expected annual cost savings of tPA were consulted. The analysis was conducted from the perspective of a universal health care system during 1 year. We estimated cost-savings with incrementally (eg, 2{\%}, 4{\%}, 6{\%}, 8{\%}, 10{\%}, 15{\%}, and 20{\%}) increased use of tPA for acute ischemic stroke nationally and provincially. RESULTS - The current average national tPA utilization is 1.4{\%}. For every increase of 2 percentage points in utilization, $757 204 (Canadian) could possibly be saved annually (95{\%} CI maximum loss of $3 823 992 to a maximum savings of $2 201 252). With a 20{\%} rate, >$7.5 million (Canadian) could be saved nationwide the first year. CONCLUSIONS - We estimate that even small increases in the proportion of all Canadian ischemic stroke patients receiving tPA could result in substantial realized savings for Canada's health care system.",
keywords = "Acute ischemic, Costs, Economics, Medical, Stroke, Thrombolysis, Tissue plasminogen activator",
author = "Yip, {Todd R.} and Demaerschalk, {Bart M}",
year = "2007",
month = "6",
doi = "10.1161/STROKEAHA.106.479477",
language = "English (US)",
volume = "38",
pages = "1952--1955",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Estimated cost savings of increased use of intravenous tissue plasminogen activator for acute ischemic stroke in Canada

AU - Yip, Todd R.

AU - Demaerschalk, Bart M

PY - 2007/6

Y1 - 2007/6

N2 - BACKGROUND AND PURPOSE - Intravenous tissue plasminogen activator (tPA) is an economically worthwhile but underused treatment option for acute ischemic stroke. We sought to identify the extent of tPA use in Canadian medical centers and the potential savings associated with increased use nationally and by province. METHODS - We determined the nationwide annual incidence of ischemic stroke from the Canadian Institute of Health Information. The proportion of all ischemic stroke patients who received tPA was derived from published data. Economic analyses that report the expected annual cost savings of tPA were consulted. The analysis was conducted from the perspective of a universal health care system during 1 year. We estimated cost-savings with incrementally (eg, 2%, 4%, 6%, 8%, 10%, 15%, and 20%) increased use of tPA for acute ischemic stroke nationally and provincially. RESULTS - The current average national tPA utilization is 1.4%. For every increase of 2 percentage points in utilization, $757 204 (Canadian) could possibly be saved annually (95% CI maximum loss of $3 823 992 to a maximum savings of $2 201 252). With a 20% rate, >$7.5 million (Canadian) could be saved nationwide the first year. CONCLUSIONS - We estimate that even small increases in the proportion of all Canadian ischemic stroke patients receiving tPA could result in substantial realized savings for Canada's health care system.

AB - BACKGROUND AND PURPOSE - Intravenous tissue plasminogen activator (tPA) is an economically worthwhile but underused treatment option for acute ischemic stroke. We sought to identify the extent of tPA use in Canadian medical centers and the potential savings associated with increased use nationally and by province. METHODS - We determined the nationwide annual incidence of ischemic stroke from the Canadian Institute of Health Information. The proportion of all ischemic stroke patients who received tPA was derived from published data. Economic analyses that report the expected annual cost savings of tPA were consulted. The analysis was conducted from the perspective of a universal health care system during 1 year. We estimated cost-savings with incrementally (eg, 2%, 4%, 6%, 8%, 10%, 15%, and 20%) increased use of tPA for acute ischemic stroke nationally and provincially. RESULTS - The current average national tPA utilization is 1.4%. For every increase of 2 percentage points in utilization, $757 204 (Canadian) could possibly be saved annually (95% CI maximum loss of $3 823 992 to a maximum savings of $2 201 252). With a 20% rate, >$7.5 million (Canadian) could be saved nationwide the first year. CONCLUSIONS - We estimate that even small increases in the proportion of all Canadian ischemic stroke patients receiving tPA could result in substantial realized savings for Canada's health care system.

KW - Acute ischemic

KW - Costs

KW - Economics

KW - Medical

KW - Stroke

KW - Thrombolysis

KW - Tissue plasminogen activator

UR - http://www.scopus.com/inward/record.url?scp=34249779838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249779838&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.106.479477

DO - 10.1161/STROKEAHA.106.479477

M3 - Article

VL - 38

SP - 1952

EP - 1955

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 6

ER -